PDGEX Performance — PGIM Target Date 2035 Fund, Class R2
Data updated: 2026-10-13
PDGEX returned +8.22% year to date and +15.46% over one year to Jul 2026. Annualised returns are +12.02% over 3 years and +6.68% over 5 years. The fund trailed its Target-Date category average: $100 invested three years ago grew to $141, against $146 for the category, and to $115 over one year, against $116. Volatility over the past three years was 8.78% a year. In the 12 months to Jul 2026 the fund lost a net $5.4M, and assets reached $49.52M.
PDGEX Growth of $100
What $100 invested in PGIM Target Date 2035 Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Target-Date category average over the same months.
| Period | PDGEX | Category average |
|---|---|---|
| 1 year (Aug 2025 – Jul 2026) | $115 | $116 |
| 3 years (Aug 2023 – Jul 2026) | $141 | $146 |
| 5 years (Aug 2021 – Jul 2026) | $138 | $142 |
| Since data start (Aug 2019 – Jul 2026) | $183 | $186 |
PDGEX Trailing Returns
Total returns to Jul 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +8.22% |
| 1 year | +15.46% |
| 3 years (annualised) | +12.02% |
| 5 years (annualised) | +6.68% |
PDGEX Annual Returns
Calendar-year total returns of PGIM Target Date 2035 Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jul) | +8.22% |
| 2025 | +14.04% |
| 2024 | +10.53% |
| 2023 | +14.10% |
| 2022 | −14.46% |
| 2021 | +16.42% |
| 2020 | +10.41% |
| 2019 (Aug–Dec) | +6.67% |
PDGEX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +2.4% | +1.8% | −4.2% | +6.2% | +2.3% | 0.0% | −0.1% | — | — | — | — | — |
| 2025 | +2.3% | +0.4% | −2.2% | 0.0% | +3.1% | +2.9% | +0.2% | +2.4% | +2.1% | +1.1% | +0.7% | +0.1% |
| 2024 | +0.1% | +2.2% | +2.4% | −3.0% | +3.5% | +1.1% | +2.0% | +2.0% | +1.8% | −2.2% | +2.9% | −2.5% |
| 2023 | +5.5% | −2.7% | +1.8% | +0.8% | −1.4% | +4.0% | +2.4% | −1.8% | −3.5% | −2.4% | +6.6% | +4.4% |
| 2022 | −3.2% | −1.3% | +1.1% | −5.6% | +0.2% | −7.1% | +6.3% | −3.5% | −8.3% | +4.7% | +6.0% | −3.5% |
| 2021 | 0.0% | +1.9% | +2.6% | +3.6% | +1.3% | +0.8% | +1.4% | +1.5% | −3.1% | +3.8% | −1.7% | +3.3% |
| 2020 | −0.8% | −5.9% | −12.0% | +8.6% | +4.0% | +2.4% | +3.8% | +4.0% | −2.5% | −1.7% | +8.5% | +3.5% |
| 2019 | — | — | — | — | — | — | — | −1.2% | +1.6% | +1.8% | +2.0% | +2.4% |
PDGEX Risk
Risk measures from monthly returns over Aug 2023 – Jul 2026.
- 3-year volatility (annualised): 8.78%
- 3-year Sharpe ratio: 0.86 (vs 4.5% risk-free rate)
- Best month: +6.60% (Nov 2023)
- Worst month: −4.23% (Mar 2026)
PDGEX Fund Flows
Monthly money in and out of PGIM Target Date 2035 Fund, from SEC Form N-PORT.
- 12-month net flow: −$5.4M
- 12-month gross sales (incl. reinvestments): $11.3M
- Sales ÷ redemptions: 0.67×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jul 2026 | $432K | $780K | −$348K |
| Jun 2026 | $469K | $318K | $151K |
| May 2026 | $424K | $8.1M | −$7.6M |
| Apr 2026 | $413K | $469K | −$56K |
| Mar 2026 | $345K | $2.5M | −$2.2M |
| Feb 2026 | $287K | $203K | $84K |
| Jan 2026 | $453K | $619K | −$166K |
| Dec 2025 | $5.7M | $1.1M | $4.6M |
| Nov 2025 | $820K | $1.2M | −$412K |
| Oct 2025 | $496K | $473K | $23K |
| Sep 2025 | $1.0M | $309K | $705K |
| Aug 2025 | $488K | $687K | −$199K |
PDGEX Assets Under Management
Net assets of PGIM Target Date 2035 Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-07-31 | $49.52M |
| 2026-04-30 | $56.26M |
| 2026-01-30 | $56.50M |
| 2025-10-31 | $52.94M |
| 2025-07-31 | $49.48M |
| 2025-04-30 | $45.79M |
| 2025-01-31 | $46.95M |
| 2024-10-31 | $43.28M |
| 2024-07-31 | $42.06M |
| 2024-04-30 | $37.89M |
| 2024-01-31 | $36.84M |
| 2023-10-31 | $44.77M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.